FDA approves Natera's Signatera CDx for bladder cancer treatment decisions
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)
May 15, 2026 12:45 PM EDTMarks the first FDA-approved use of personalized molecular residual disease (MRD) testing to guide treatment decisions
Solidifies Nateras Treatment on MRD (TOMR) approach as the new standard of care in MIBC, enabling precision interventions for MRD-positive patients while sparing MRD-negative patients from potentially unnecessary treatment
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc.... More
